AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TRNS

Dominach Oksana S. sold $626K of TRNS

Dominach Oksana S. sold 7,312 shares of TRANSCAT INC (TRNS) at $85.60 ($0.63M total) on 2026-09-02.

Original reporting
SEC EDGAR · Dominach Oksana S.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRNS
Neutral
medium confidence
Mentioned
$TRNS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRNSNeutralLow
01

Why it matters

The director's sale is modest and unlikely to move the stock materially.

02

Market read

Limited relevance; primarily of interest to existing shareholders and insiders.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs are not disclosed.

Relevance 5/10Novelty 5/10Timing: filed today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$TRNSNeutralMedium confidence
Context

Director Oksana Dominach sold 7,312 shares of Transcat Inc for $625,876, reducing her stake to 4,346 shares.

Expected impact

Minor downward pressure, likely within normal trading range.

Evidence & confidence

Sale size is small relative to market cap and no broader context indicates distress.

Market effects

Sector

None significant for the industrial equipment sector.

Regional

No regional effect.

Global

Limited to Transcat shareholders.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a signal of underlying weakness.

Key entities

  • Company
    Transcat Inc

    Publicly traded industrial equipment manufacturer (ticker TRNS).

  • Insider
    Oksana S. Dominach

    Director of Transcat Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRNS insider trading history →

Related articles

$TRNSMedAI 8/10

Transcat (TRNS) Q2 2027 Earnings Call Transcript

Transcat (TRNS) reported Q2 2027 revenue of $97.1M, up 18%, with service revenue growing 23% and distribution revenue up 10%. Gross profit increased 22%, and adjusted EBITDA grew 23% to $14.9M. The company cited strong demand in regulated end markets and strategic acquisitions, including Southeastern Biomedical Associates, as drivers of growth. Service gross margins expanded 220 basis points to 34.4%.

finance.yahoo.com
$TRNSMed

Transcat Q2 Earnings Call Highlights

Transcat (TRNS) reported Q2 growth in distribution revenue (10% to $32.3M) and adjusted EBITDA (23% to $14.9M). Management raised its fiscal 2027 service organic revenue growth outlook to low-double-digits and expects service gross-margin expansion. The company highlighted demand in regulated markets and completed an acquisition to expand its biomedical calibration footprint.

finance.yahoo.com
$TRNSMed

Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Significant Service Gross Margin…

TRANSCAT INC (TRNS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE Transcat, Inc. 35 Vantage Point Drive • Rochester • NY • 14624 • Phone: (585) 352-7777 Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Significant Service Gross Margin Expansion •

SEC EDGAR 8-K